Source-backed half-life profile
Diazepam half-life calculator
Diazepam is a long-tail benzodiazepine page where metabolites are central to the interpretation.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
What a careful reader should notice first
The curve shows one representative value, but the practical story can involve residual effects, active metabolites, and repeated-use overlap.
Source angle
Read labels and reviews for parent-drug versus metabolite language before treating a single number as the whole profile.
Do not use it for
Do not use the page to infer taper schedules, next-day impairment, or safe timing with alcohol or other depressants.
Best next step
Pair this page with terminal-versus-effective half-life and active-metabolite explainers.
Diazepam: evidence and interpretation notes
This curve is diazepam, not its entire active family
Diazepam is a case where naming the modeled analyte is essential. Product labeling describes a prolonged terminal elimination phase for the parent drug, extending up to about 48 hours, while the active metabolite N-desmethyldiazepam can persist considerably longer. HalfLifeDB uses 30 hours as a representative adult parent-drug value, not as a combined estimate for diazepam and every active metabolite.
That distinction changes how the chart should be read. A parent-only line can decline exactly as calculated while metabolite exposure follows a second, slower trajectory that is not shown. Adding those quantities would require a multi-compartment, multi-analyte model and study-specific concentration data.
| Evidence source | What it contributes | Important limit |
|---|---|---|
| DailyMed injection labeling | Parent terminal-phase context and the long-lived active metabolite | Injection labeling should not be generalized to every formulation or individual |
| Griffin benzodiazepine review | Distribution, oxidative metabolism, and the clinical importance of active metabolites | It is a class review, not a new diazepam trial |
| PubChem identity record | Compound identity and chemistry | It does not establish the representative 30-hour selection |
Distribution and metabolism lengthen the story
The Griffin review describes benzodiazepines as highly protein bound and widely distributed, with lipophilic agents accumulating in lipid-rich tissues. It identifies diazepam’s active metabolites, including desmethyldiazepam, temazepam, and oxazepam. The review also notes that active metabolites deserve particular attention in older adults and people with substantial hepatic disease.
Those observations explain why a neat single line can understate practical complexity. Redistribution can shape early concentration changes, hepatic metabolism creates additional active compounds, and repeated exposure can produce overlap from one interval to the next.
Why 30 hours is still useful
Thirty hours is not presented as the one correct diazepam half-life. It is a transparent plotting choice within the adult parent-drug time scale described by labeling. It lets a reader compare a long parent curve with shorter benzodiazepine profiles while keeping the metabolite limitation visible in the model label and source notes.
The curve cannot determine sedation, memory effects, coordination, withdrawal, or safe activity timing. It also cannot support medication changes. Its value is conceptual: diazepam shows why a long parent half-life plus longer-lived active metabolites requires more caution than a single headline number can convey.
Reading this curve
HalfLifeDB uses 30 h as a representative input for Diazepam parent compound. In the simplified model, about 57.4% remains after 24 hours and about 3% remains after five half-lives, or roughly 6.3 days.
This is a day-scale half-life. Repeated exposure, timing, and source context start to matter more than a single snapshot of the curve. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
benzodiazepine context
Benzodiazepine half-life estimates can be especially sensitive to active metabolites, redistribution, age, liver function, and repeated use.
- A long terminal half-life does not mean effects remain constant for the whole period.
- Shorter-acting entries can still have residual effects after the main subjective effects fade.
- Repeated exposure can create overlap that a single-dose curve does not show.
Diazepam timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 24 h | 57.4% | Meaningful modeled decline, not near-zero |
| 3.0 days | 18.9% | Long-tail portion of the model |
| 5.0 days | 6.25% | Low modeled remainder, not a clearance guarantee |
| 7.0 days | 2.06% | Low modeled remainder, not a clearance guarantee |
| 14 days | 0.04% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Diazepam within the benzodiazepine group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- Alprazolam (11.2 h)
Pharmacokinetics at a glance
| Representative half-life | 30 h |
|---|---|
| Modeled analyte or phase | Diazepam parent compound |
| Curve type | Normalized, first-order decline |
Selection note: The 30-hour curve is a representative adult parent-drug value. Product labeling describes a prolonged terminal phase up to 48 hours and an active metabolite lasting up to 100 hours.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: Diazepam injection.Official labeling describing the prolonged parent-drug terminal phase and the still longer-lived active metabolite.
- Identity record PubChem Compound Summary: Diazepam.Compound identity record; background only, not the numerical basis for the curve.
- Full-text research Griffin CE et al. Benzodiazepine pharmacology and central nervous system effects (2013).Full-text clinical review explaining diazepam distribution, active metabolites, and why patient context changes interpretation.
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the benzodiazepine group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and profile review log before using the model for comparison.